Stock Report

Download full stock data and analysis for free Last Updated: 30-Aug-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Arrowhead Pharmaceuticals (ARWR) Peer Comparison

Stock Card factsheet share-fund-plan-icon

$84.87

up-down-arrow $-3.73 (-4.20%)

As on 28-Aug-2026 13:33EDT

Market cap

info icon

$12,305 Mln

Revenue (TTM)

info icon

$670 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

26.4

Div. Yield

info icon

0 %

Edit peer-selector-edit
Arrowhead Pharmaceuticals (ARWR) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Market cap ($ Mln)
 12,305 17,326 16,614 13,400 12,277
Revenue ($ Mln)
 670 2,782 1,054 2,436 1,664
Net Profit ($ Mln)
 -319.95 491.50 755.85 860.62 413.60
Net Margin (%)
 -47.79 17.67 71.69 35.33 24.86
RoE (%)
 -71.14 110.09 -- 42.98 430.03
Price to Earnings
 -- 36.49 19.38 17.01 31.17
Price-To-Book
 26.44 39.43 10.05 7.27 83.92

Income Statement ($ Mln)

Arrowhead Pharmaceuticals (ARWR) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Operating Revenue arrow
669.50 2,782.29 1,054.37 2,435.92 1,663.74
Cost of Revenue arrow
19.14 1,982.07 103.47 85.67 363.07
Gross Profit arrow
829.45 760.62 588.53 2,236.43 1,091.18
Operating Expenses arrow
895.93 216.81 841.45 1,378.74 356.18
Operating Profit (EBIT) arrow
-226.44 583.40 109.45 971.51 944.49
Other Income arrow
0.00 0.00 0.00 0.00 0.00
Profit before Tax arrow
-252.08 598.92 101.11 1,035.47 583.34
Provision for Tax arrow
20.05 107.42 -654.74 174.84 169.74
Profit after Tax (Net Income) arrow
-319.95 491.50 755.85 860.62 413.60
Minority Interest arrow
-47.83 0.00 0.00 0.00 0.00
Consolidated Profit arrow
0.00 0.00 0.00 0.00 0.00

Liabilities ($ Mln)

Arrowhead Pharmaceuticals (ARWR) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Shareholder's Funds arrow
465.53 433.86 1,435.90 1,843.76 143.54
Minority Interest arrow
-47.83 0.00 0.00 0.00 0.00
Non-Current Liabilities arrow
1,362.63 187.89 384.48 288.55 2,089.43
Current Liabilities arrow
283.35 1,435.43 464.70 361.93 344.44
Total Liabilities arrow
1,385.30 1,975.47 1,302.02 2,844.42 2,525.32

Assets ($ Mln)

Arrowhead Pharmaceuticals (ARWR) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Non-Current Assets arrow
440.60 1,006.90 895.24 1,243.41 1,644.38
Current Assets arrow
1,671.41 1,050.29 1,389.84 1,250.82 933.02
Total Assets arrow
1,385.30 1,975.47 1,302.02 2,844.42 2,525.32
Total Debt* arrow
864.07 120.10 449.89 165.93 2,146.65
Net Current Assets arrow
1,388.07 -385.14 0.00 888.90 588.59

Cashflow ($ Mln)

Arrowhead Pharmaceuticals (ARWR) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Cash From Operating Activities arrow
179.55 713.22 51.77 884.27 651.56
Cash Flow from Investing Activities arrow
-129.29 -31.14 -8.15 350.44 -545.81
Cash from Financing Activities arrow
74.01 -860.39 34.89 -969.59 -85.17
Net Cash Inflow / Outflow arrow
-- -- -- -- --

Ratios

Profitability Ratios

 Arrowhead Pharmaceuticals (ARWR) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
ROCE (%) arrow
-0.17 53.56 -30.01 32.82 15.61
ROE (%) arrow
-71.14 110.09 163.18 42.98 430.03
ROA (%) arrow
-16.12 15.64 26.53 29.32 16.19
EBIT Margin (%) arrow
-0.77 21.13 5.73 31.04 36.28
Net Margin (%) arrow
-47.79 17.67 71.69 35.33 24.86
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Arrowhead Pharmaceuticals (ARWR) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Revenue Growth (%) arrow
12.22 24.67 114.85 9.23 41.15
EBIT Growth (%) arrow
93.17 18.70 136.39 -3.99 -14.99
Net Profit Growth (%) arrow
-115.58 17.50 378.76 42.89 -25.78
EPS Growth (%) arrow
-73.87 26.84 353.27 50.42 -23.48
Book Value Growth (%) arrow
-13.57 164.02 816.12 -0.70 -55.81

Valuation Ratios

 Arrowhead Pharmaceuticals (ARWR) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Price / Earnings arrow
-2,869.63 36.06 -59.76 15.79 24.99
Price / Book Value arrow
10.04 35.44 -80.42 5.72 162.23
Dividend Yield (%) arrow
-- -- -- -- --
EV/EBITDA arrow
25.04 28.08 -121.54 12.44 17.31
Market Cap ($ Cr) arrow
-- -- -- -- --

Solvency Ratios

 Arrowhead Pharmaceuticals (ARWR) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Debt to Equity arrow
1.77 0.00 0.00 0.00 13.50
Short term debt to equity ratio arrow
0.09 0.00 0.05 0.00 1.46
Current Ratio arrow
5.90 0.73 2.99 3.46 2.71
Quick Ratio arrow
5.90 0.73 2.32 3.38 2.31
Interest Coverage arrow
-1.72 -- 1.62 -- 29.73

Operating Efficiency Ratios

 Arrowhead Pharmaceuticals (ARWR) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Debtors to sales (%) arrow
1.28 15.88 21.25 13.74 27.40
Asset Turnover arrow
0.34 0.89 0.37 0.83 0.65
Receivable days arrow
1.50 50.42 85.52 43.48 98.04
Inventory Days arrow
-- -- 1,056.70 96.17 190.34
Payable days arrow
221.81 6.26 331.01 147.97 18.62
Cash Conversion Cycle arrow
-- -- 811.21 -8.32 269.75
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...